All News

pills-384846_640%20%281%29.jpg

The complexity of opioid use in spondyloarthritis

Robert Chao, MD

A few things we know about opioids: use is common; it’s not efficacious in the treatment of spondyloarthritis; and, there is an opioid epidemic and its users are stigmatized. Abstract 0402 is a retrospective study that looked at patients with psoriatic arthritis or ankylosing spondylitis in the FORWARD databank. It sheds new light and leaves us with some food for thought

Read Article
Back Pain

Thinking Outside the Box: Novel Strategies for Early Detection of AxSpA

Akhil Sood, MD

Strategies to identify patients with suspected inflammatory back pain in the general population is critical for timely and proper diagnosis.

Read Article
Target

Dual inhibition of IL17A and IL17F in AxSpA

Antoni Chan, MD, PhD

A new target for treatment in AxSpA is the dual inhibition of IL17A and IL17F (IL17A/F). IL17A is a key driver of the inflammation in the AxSpA and Psoriatic Arthritis (PsA). IL17A and its structurally related IL17F share biologic functional properties. Inhibition of both cytokines (IL17A/F) should result in a greater clinical benefit in AxSpA and PsA than IL17A inhibition alone.

Read Article
syringe,needle,vaccine

Vaccine Efficacy in Patients with Seronegative Spondyloarthritis

Catherine Sims, MD

Vaccine efficacy remains an important and highly discussed topic at this year’s annual meeting given the ongoing COVID-19 global health crisis, current influenza season, and recently published 2022 ACR guidelines for vaccinations in patients with rheumatic and musculoskeletal diseases.

Read Article
ACR Best

ACR Best Abstracts - Day 2

Jack Cush, MD

Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.

Here are the RheumNow faculty selections for #ACRbest abstracts today:

Read Article
Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199 https://t.co/Pwg6GKu7Gg https://t.co/wPF0pu1UDa

Links:

Richard Conway RichardPAConway ( View Tweet)
Are your SpA pts planning on conceiving? Be careful with NSAID use French study found age and NSAID use associated with longer time-to-conception. Factors not associated: smoking, BASDAI score, DMARD use #ACRBest Abs#1673 @RheumNow #ACR22 https://t.co/D63XTY7IB8
Robert B Chao, MD doctorRBC ( View Tweet)
Ab1673 #ACR22: Time-to-Conception (T2C) in SpA Prosp, observ 88F, 56 pregnancy Subfertility in 45% F, T2C 16 mos Risks: age, NSAID Rx: NSAIDs (26%), steroids (9%), csDMARD (14%), biol (69%) No control grp - Is it cause or correlate? 2020 Repro G/L rec d/c NSAID @RheumNow #ACRBest https://t.co/e51XjhyH9u
Eric Dein ericdeinmd ( View Tweet)
Hamroun et al. Preconceptual NSAID use assoc impaired fertility in SpA, HR 3.01 for time-to-conception @RheumNow #ACR22 Abstr#1673 https://t.co/jresR9MfXF https://t.co/flyfJob9un

Links:

Richard Conway RichardPAConway ( View Tweet)
Dr S Hamroun shares their study data on factors assoc w/ time-to-conception in ♀️ w/ SpA: ❗Pre-conceptional NSAID use ❗Age Thought-provoking. Time to re-evaluate our NSAID prescribing practices for ♀️ SpA? #ACR22 @RheumNow ABST#1673 https://t.co/cHED0I3vUe
sheila RHEUMarampa ( View Tweet)
Dr. Ogdie proposes a whole-patient care approach to the treat-to-target strategy in SpA with QoL as the most important target. #ACR22 @Rheumnow @rheumarhyme @trishiemd https://t.co/GjLt2Nym3I
sheila RHEUMarampa ( View Tweet)
L14 #ACR22 Bimekizumab BE MOBILE 1 and 2 Sustained efficacy to Wk52. ASAS40 in BKZ incr from W16 (47% nrAxSpA, 45% AS) to W52 (61%, 58%). Efficacy in TNF-naive & TNF-failure. AEs: Nasopharyngitis (12% nrAxSpA, 9% AS), URI (9, 6%), candidiasis (7, 6%), COVID (7, 2%) @RheumNow https://t.co/G31PrfqtVu
Eric Dein ericdeinmd ( View Tweet)
L15 #ACR22 SURPASS: SEC vs bsADA (SDZ-ADL) on radiographic progression of AS P3b: SEC 150 mg v SEC 300 v SDZ-ADL Wk 104: no radiographic progression in 66%, 67%, 66% - no statistical significance Hard to assess as overall, low rate of progression @RheumNow

Eric Dein ericdeinmd ( View Tweet)

Does tofacitinib work better in patients with PsA and AS who smoke? Abstract #1036 #ACR22 @RheumNow 🚬519 ever smokers 🚭767 never smokers 💉In PsA only, TOF efficacy was greater in ever smokers vs. PBO ✋Overall, efficacy was generally comparable in ever v. never 🚬

Catherine Sims, MD DrCassySims ( View Tweet)

Abstract #PP25 Patient mantra on life with SpA: “not to over-exert the body on your good days and always strive to be active on your bad days” Patient recommended exercise: 🏓table tennis 🏊‍♂️swimming 🧘yoga 🤸tai chi #ACR22 @RheumNow

Catherine Sims, MD DrCassySims ( View Tweet)

Bimekizumab (BKZ) in AxSpA to Wk52 ◦ sustained efficacy ◦ suppression of inflammation ◦ improvements in function and quality of life ◦ no new safety signals were observed ◦ consistent with the safety profileWk24 data Baraliakos #L14 https://t.co/gk23g4vqQl #ACR22 @RheumNow

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)

Mortality in patients with SpA Abstract #0569 #ACR22 @RheumNow ✏️systematic review/meta-analysis of 19 studies ✋No increased mortality in patients with PsA compared to gen. pop. 🦠Infection, 🫀CV, and 🫁 pulm. specific mortality sig. higher in PsA patients

Catherine Sims, MD DrCassySims ( View Tweet)

Karmacharya @rheum_cat et al. Comorbidity clusters in AS. Depression cluster associated higher disease activity and worse function over time. @RheumNow #ACR22 Abstr#1609 https://t.co/lFVoyhy5UQ https://t.co/26EjzXULGr

Links:

Richard Conway RichardPAConway ( View Tweet)
Spinal lesions on MRI in axSpA is ~3% in patients with negative imaging in SIJ on MRI or X-ray. Agreement in >5/9 central readers. Frequency of spinal vertebral corner BME lesions was significantly higher these cases. Maksymovych Abs#2257 https://t.co/56yxGxBgLp #ACR22 @RheumNow https://t.co/CkJ9o2dJuT

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
Does lifestyle impact Tx. response? #Abstr 1510 looked at effect of lifestyle on TNFi response in #axSpA - The study found higher BMI (obese, overweight) and smoking were less likely to respond to TNFi - Important to discuss lifestyle when starting tx. @RheumNow #ACR22 https://t.co/z98DFMLxu3
Akhil Sood MD AkhilSoodMD ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×